NEW YORK, Nov. 09, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Spectrum Pharmaceuticals, Inc. securities (NASDAQ:SPPI) from December 16, 2015 through September 16, 2016, both dates inclusive (the “Class Period”) of the important November 21, 2016 lead plaintiff deadline in the class action filed by the firm.
To join the Spectrum class action, go to http://www.rosenlegal.com/cases-955.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA previously questioned whether the data from the 611 and 612 Studies were clinically meaningful; (2) the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) as a result, defendants’ public statements about Spectrum’s business, operations and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 21, 2016. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-955.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 



